Its a specy. Lots of variables. If the trial is successful it will go gangbusters.
I think one problem with PAB is that they aren't directly in control of these basic functions. ie. the manufacture of PAT-SM6, in USA, they have to accept the progress of the third party.
They had trouble with the manufacture a few months ago and said it was fixed, but there could be another problem.
Please correct me if Im wrong, but doesnt PAB use plants to create the antibodies and controls which antibodies are created by modifying the sugars ? ie. glycoengineering
PaB is the first to develop this technique. Its produces alot of antibodies and does it very cheaply.
Its revolutionary and super-cheap ! and so far doesnt seem to work very well....
Its funny the effecttiveness doesnt seem to be the problem, its making the stuff !
- Forums
- ASX - By Stock
- What's the root cause of PAB's poor SP performance?
Its a specy. Lots of variables. If the trial is successful it...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.3¢ | $10.97K | 3.626M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
41 | 31554019 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 27089307 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
40 | 31054019 | 0.003 |
24 | 27131332 | 0.002 |
14 | 54551998 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 27089307 | 15 |
0.005 | 11226512 | 10 |
0.006 | 3371450 | 5 |
0.007 | 6601356 | 5 |
0.008 | 1221910 | 4 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
PAB (ASX) Chart |